会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • N2S2 chelate-targeting ligand conjugates
    • N2S2螯合靶向配体缀合物
    • US09050378B2
    • 2015-06-09
    • US10732919
    • 2003-12-10
    • David J. YangDong-Fang YuChang-Sok OhJerry L. Bryant, Jr.
    • David J. YangDong-Fang YuChang-Sok OhJerry L. Bryant, Jr.
    • A61K51/10A61K51/04A61K51/08
    • A61K51/1093A61K51/0497A61K51/088
    • The invention provides, in a general sense, a new labeling strategy employing compounds that are N2S2 chelates conjugated to a targeting ligand, wherein the targeting ligand is a disease cell cycle targeting compound, a tumor angiogenesis targeting ligand, a tumor apoptosis targeting ligand, a disease receptor targeting ligand, amifostine, angiostatin, monoclonal antibody C225, monoclonal antibody CD31, monoclonal antibody CD40, capecitabine, a COX-2 inhibitor, deoxycytidine, fullerene, herceptin, human serum albumin, lactose, leuteinizing hormone, pyridoxal, quinazoline, thalidomide, transferrin, or trimethyl lysine. The present invention also pertains to kits employing the compounds of interest, and methods of assessing the pharmacology of an agent of interest using the present compounds.
    • 本发明在一般意义上提供了使用与靶向配体缀合的N 2 S 2螯合物的化合物的新标记策略,其中靶向配体是疾病细胞周期靶向化合物,肿瘤血管生成靶向配体,肿瘤凋亡靶向配体, 疾病受体靶向配体,氨磷汀,血管抑素,单克隆抗体C225,单克隆抗体CD31,单克隆抗体CD40,卡培他滨,COX-2抑制剂,脱氧胞苷,富勒烯,赫赛汀,人血清白蛋白,乳糖,促黄体激素,吡哆醛,喹唑啉,沙利度胺, 转铁蛋白或三甲基赖氨酸。 本发明还涉及使用目的化合物的试剂盒,以及使用本发明化合物评价感兴趣剂的药理学的方法。
    • 2. 发明申请
    • N2S2 chelate-targeting ligand conjugates
    • N2S2螯合靶向配体缀合物
    • US20050129619A1
    • 2005-06-16
    • US10732919
    • 2003-12-10
    • David YangDong-Fang YuChang-Sok OhJerry Bryant
    • David YangDong-Fang YuChang-Sok OhJerry Bryant
    • A61K51/04A61K51/08A61K51/10A61K49/00A61K51/00C07F5/00C07K16/46
    • A61K51/1093A61K51/0497A61K51/088
    • The invention provides, in a general sense, a new labeling strategy employing compounds that are are N2S2 chelates conjugated to a targeting ligand, wherein the targeting ligand is a disease cell cycle targeting compound, a tumor angiogenesis targeting ligand, a tumor apoptosis targeting ligand, a disease receptor targeting ligand, amifostine, angiostatin, monoclonal antibody C225, monoclonal antibody CD31, monoclonal antibody CD40, capecitabine, a COX-2 inhibitor, deoxycytidine, fullerene, herceptin, human serum albumin, lactose, leuteinizing hormone, pyridoxal, quinazoline, thalidomide, transferrin, or trimethyl lysine. The present invention also pertains to kits employing the compounds of interest, and methods of assessing the pharmacology of an agent of interest using the present compounds.
    • 本发明在一般意义上提供了使用与靶向配体缀合的N 2 S 2 N 2螯合物的化合物的新标记策略,其中靶向配体是疾病 细胞周期靶向化合物,肿瘤血管生成靶向配体,肿瘤凋亡靶向配体,疾病受体靶向配体,氨磷汀,血管抑素,单克隆抗体C225,单克隆抗体CD31,单克隆抗体CD40,卡培他滨,COX-2抑制剂,脱氧胞苷,富勒烯 ,赫赛汀,人血清白蛋白,乳糖,促黄体激素,吡哆醛,喹唑啉,沙利度胺,转铁蛋白或三甲基赖氨酸。 本发明还涉及使用目的化合物的试剂盒,以及使用本发明化合物评价感兴趣剂的药理学的方法。